vs
Side-by-side financial comparison of Intellia Therapeutics, Inc. (NTLA) and Spok Holdings, Inc (SPOK). Click either name above to swap in a different company.
Spok Holdings, Inc is the larger business by last-quarter revenue ($33.9M vs $23.0M, roughly 1.5× Intellia Therapeutics, Inc.). Spok Holdings, Inc runs the higher net margin — 8.7% vs -416.2%, a 424.8% gap on every dollar of revenue. On growth, Intellia Therapeutics, Inc. posted the faster year-over-year revenue change (78.8% vs -0.1%). Spok Holdings, Inc produced more free cash flow last quarter ($10.1M vs $-69.4M). Over the past eight quarters, Spok Holdings, Inc's revenue compounded faster (-1.5% CAGR vs -10.8%).
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineere...
Spok Holdings, Inc. is a global provider of critical communication solutions primarily serving the healthcare industry. It offers unified clinical communication platforms, secure messaging tools, alerting systems, and on-call scheduling software that help care teams coordinate efficiently, cut response times, and boost patient safety across medical facilities.
NTLA vs SPOK — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $23.0M | $33.9M |
| Net Profit | $-95.8M | $2.9M |
| Gross Margin | — | 76.7% |
| Operating Margin | -428.9% | 11.6% |
| Net Margin | -416.2% | 8.7% |
| Revenue YoY | 78.8% | -0.1% |
| Net Profit YoY | 25.7% | -19.6% |
| EPS (diluted) | $-0.81 | $0.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $23.0M | $33.9M | ||
| Q3 25 | $13.8M | $33.9M | ||
| Q2 25 | $14.2M | $35.7M | ||
| Q1 25 | $16.6M | $36.3M | ||
| Q4 24 | $12.9M | $33.9M | ||
| Q3 24 | $9.1M | $34.9M | ||
| Q2 24 | $7.0M | $34.0M | ||
| Q1 24 | $28.9M | $34.9M |
| Q4 25 | $-95.8M | $2.9M | ||
| Q3 25 | $-101.3M | $3.2M | ||
| Q2 25 | $-101.3M | $4.6M | ||
| Q1 25 | $-114.3M | $5.2M | ||
| Q4 24 | $-128.9M | $3.6M | ||
| Q3 24 | $-135.7M | $3.7M | ||
| Q2 24 | $-147.0M | $3.4M | ||
| Q1 24 | $-107.4M | $4.2M |
| Q4 25 | — | 76.7% | ||
| Q3 25 | — | 78.3% | ||
| Q2 25 | — | 79.5% | ||
| Q1 25 | — | 80.1% | ||
| Q4 24 | — | 78.5% | ||
| Q3 24 | — | 79.5% | ||
| Q2 24 | — | 78.9% | ||
| Q1 24 | — | 79.5% |
| Q4 25 | -428.9% | 11.6% | ||
| Q3 25 | -808.9% | 12.9% | ||
| Q2 25 | -772.2% | 15.1% | ||
| Q1 25 | -726.6% | 16.6% | ||
| Q4 24 | -1059.9% | 13.7% | ||
| Q3 24 | -1589.0% | 14.2% | ||
| Q2 24 | -1998.6% | 13.2% | ||
| Q1 24 | -394.0% | 14.0% |
| Q4 25 | -416.2% | 8.7% | ||
| Q3 25 | -735.2% | 9.5% | ||
| Q2 25 | -710.8% | 12.8% | ||
| Q1 25 | -687.6% | 14.3% | ||
| Q4 24 | -1001.2% | 10.8% | ||
| Q3 24 | -1489.5% | 10.5% | ||
| Q2 24 | -2112.6% | 10.1% | ||
| Q1 24 | -371.3% | 12.1% |
| Q4 25 | $-0.81 | $0.13 | ||
| Q3 25 | $-0.92 | $0.15 | ||
| Q2 25 | $-0.98 | $0.22 | ||
| Q1 25 | $-1.10 | $0.25 | ||
| Q4 24 | $-1.27 | $0.17 | ||
| Q3 24 | $-1.34 | $0.18 | ||
| Q2 24 | $-1.52 | $0.17 | ||
| Q1 24 | $-1.12 | $0.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $449.9M | $25.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $671.4M | $146.4M |
| Total Assets | $842.1M | $206.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $449.9M | $25.3M | ||
| Q3 25 | $511.0M | $21.4M | ||
| Q2 25 | $459.7M | $20.2M | ||
| Q1 25 | $503.7M | $19.9M | ||
| Q4 24 | $601.5M | $29.1M | ||
| Q3 24 | $658.1M | $27.8M | ||
| Q2 24 | $691.1M | $23.9M | ||
| Q1 24 | $791.3M | $23.3M |
| Q4 25 | $671.4M | $146.4M | ||
| Q3 25 | $748.4M | $148.7M | ||
| Q2 25 | $715.3M | $150.9M | ||
| Q1 25 | $779.9M | $151.7M | ||
| Q4 24 | $872.0M | $154.7M | ||
| Q3 24 | $962.6M | $156.3M | ||
| Q2 24 | $971.1M | $158.2M | ||
| Q1 24 | $1.0B | $160.2M |
| Q4 25 | $842.1M | $206.1M | ||
| Q3 25 | $925.3M | $209.7M | ||
| Q2 25 | $898.9M | $208.7M | ||
| Q1 25 | $986.2M | $204.5M | ||
| Q4 24 | $1.2B | $217.1M | ||
| Q3 24 | $1.2B | $216.8M | ||
| Q2 24 | $1.2B | $216.4M | ||
| Q1 24 | $1.3B | $215.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-69.3M | $11.5M |
| Free Cash FlowOCF − Capex | $-69.4M | $10.1M |
| FCF MarginFCF / Revenue | -301.6% | 29.9% |
| Capex IntensityCapex / Revenue | 0.5% | 4.1% |
| Cash ConversionOCF / Net Profit | — | 3.93× |
| TTM Free Cash FlowTrailing 4 quarters | $-395.9M | $25.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-69.3M | $11.5M | ||
| Q3 25 | $-76.9M | $8.1M | ||
| Q2 25 | $-99.6M | $7.0M | ||
| Q1 25 | $-148.9M | $2.3M | ||
| Q4 24 | $-85.2M | $8.4M | ||
| Q3 24 | $-84.8M | $11.1M | ||
| Q2 24 | $-58.2M | $7.4M | ||
| Q1 24 | $-120.7M | $2.0M |
| Q4 25 | $-69.4M | $10.1M | ||
| Q3 25 | $-76.9M | $7.6M | ||
| Q2 25 | $-99.9M | $6.0M | ||
| Q1 25 | $-149.7M | $1.5M | ||
| Q4 24 | $-86.2M | $7.5M | ||
| Q3 24 | $-86.1M | $10.3M | ||
| Q2 24 | $-59.2M | $6.8M | ||
| Q1 24 | $-123.2M | $1.1M |
| Q4 25 | -301.6% | 29.9% | ||
| Q3 25 | -558.2% | 22.4% | ||
| Q2 25 | -701.0% | 16.8% | ||
| Q1 25 | -900.1% | 4.2% | ||
| Q4 24 | -669.4% | 22.3% | ||
| Q3 24 | -945.2% | 29.4% | ||
| Q2 24 | -850.9% | 20.0% | ||
| Q1 24 | -425.7% | 3.2% |
| Q4 25 | 0.5% | 4.1% | ||
| Q3 25 | 0.2% | 1.6% | ||
| Q2 25 | 1.7% | 2.9% | ||
| Q1 25 | 4.4% | 2.1% | ||
| Q4 24 | 7.6% | 2.5% | ||
| Q3 24 | 14.0% | 2.4% | ||
| Q2 24 | 14.5% | 1.9% | ||
| Q1 24 | 8.7% | 2.5% |
| Q4 25 | — | 3.93× | ||
| Q3 25 | — | 2.54× | ||
| Q2 25 | — | 1.55× | ||
| Q1 25 | — | 0.43× | ||
| Q4 24 | — | 2.31× | ||
| Q3 24 | — | 3.03× | ||
| Q2 24 | — | 2.17× | ||
| Q1 24 | — | 0.47× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NTLA
| Avencell Therapeutics Inc | $21.0M | 91% |
| Other | $1.0M | 4% |
| Avencell | $1.0M | 4% |
SPOK
| Paging | $16.8M | 50% |
| Software Operations | $16.0M | 47% |
| License | $1.2M | 4% |
